The present study also provided mechanistic insight into the SETD2-dependent epigenetic regulation of ccRCC tumor suppression, indicating that SETD2 may serve as a therapeutic target for ccRCC treatment. This evidence concerns the gene SETD2 and nonpapillary renal cell carcinoma.